鍏充簬澶氬彂鎬х‖鍖�<\/u><\/b> <\/p> \n

澶氬彂鎬х‖鍖栨槸涓€绉嶄互涓灑绁炵粡绯荤粺鐐庢€ц劚楂撻灅鐥呭彉涓轰富瑕佺壒鐐圭殑鍏嶇柅浠嬪鎬х柧鐥咃紝鍏剁梾鍥犲皻涓嶆槑纭紝鍙兘涓庨仐浼犮€佺幆澧冦€佺梾姣掓劅鏌撶瓑澶氱鍥犵礌鐩稿叧^{[1]<\/sup>銆傞珦闉樻崯浼や細骞叉壈澶ц剳涓庤韩浣撳叾浠栭儴浣嶄箣闂寸殑閫氫俊[3]<\/sup>锛屾渶缁堝鑷寸缁忛€€琛屾€ф崯瀹筹紝杩欎竴杩囩▼鐩墠灏氫笉鍙€�[10]<\/sup>銆�<\/p> \n}

澶嶅彂鍨嬪鍙戞€х‖鍖栧寘鎷复搴婂绔嬬患鍚堝緛銆佸鍙�-缂撹В鍨嬬柧鐥呭拰娲诲姩鎬х户鍙戣繘灞曞瀷鐤剧梾^{[11]<\/sup>銆傚叾涓紝澶嶅彂-缂撹В鍨嬬柧鐥呮槸璇婃柇鏃舵渶甯歌鐨勭被鍨嬶紝80%-85%鐨勬偅鑰呭垵璇婃椂琚瘖鏂负澶嶅彂-缂撹В鍨嬬柧鐥咃紝鍏惰〃鐜颁负鏄庢樉鐨勫鍙戝拰缂撹В杩囩▼锛屾瘡娆″彂浣滃悗鍧囧熀鏈仮澶嶏紝涓嶇暀鎴栦粎鐣欎笅杞诲井鍚庨仐鐥�[1]<\/sup>銆傜害10%-15%鐨勬偅鑰呰璇婃柇涓鸿繘灞曞瀷鐤剧梾[11]<\/sup>銆�<\/p> \n}

鍏充簬鐑弨瑗夸簹<\/u><\/b>^{®<\/sup><\/u><\/b>锛堢洂閰稿ゥ鎵庤帿寰疯兌鍥婏級<\/u><\/b><\/p> \n}

鐑弨瑗夸簹<\/i>鏄竴绉嶅彛鏈嶉灅姘ㄩ唶1-纾烽吀锛圫1P锛夊彈浣撹皟鑺傚墏锛屽彲楂樹翰鍜屽姏缁撳悎S1P鍙椾綋1鍜�5锛圫1P_{1<\/sub>鍜孲1P5<\/sub>锛�^{[12]<\/sup>銆�鐑弨瑗夸簹<\/i>鍙€傚害鎶戝埗娣嬪反缁嗚優杩佸嚭锛屽噺灏戝鍛ㄨ涓穻宸寸粏鑳炴暟閲�[7]<\/sup>銆�鐑弨瑗夸簹<\/i>瀵瑰鍙戞€х‖鍖栧彂鎸ユ不鐤椾綔鐢ㄧ殑鏈哄埗灏氫笉瀹屽叏鏄庣‘锛屽彲鑳戒笌鍑忓皯娣嬪反缁嗚優鍚戜腑鏋㈢缁忕郴缁熺殑杩佺Щ鐩稿叧[7]<\/sup>銆�<\/p> \n}}

鐑弨瑗夸簹<\/i>宸插湪鍏ㄧ悆澶氫釜鍥藉鍜屽湴鍖烘壒鍑嗙敤浜庢不鐤楁垚浜哄鍙戝瀷澶氬彂鎬х‖鍖栫棁鍜屼腑搴﹁嚦閲嶅害娲诲姩鎬ф簝鐤℃€х粨鑲犵値鎴愪汉鎮ｈ€呫€�<\/p> \n

娉細鐑弨瑗夸簹婧冪枴鎬х粨鑲犵値閫傚簲鐥囧皻鏈湪涓浗鑾锋壒<\/i><\/p> \n

^{[1]銆婂鍙戞€х‖鍖栬瘖鏂拰娌荤枟涓浗涓撳鍏辫瘑锛�2018鐗堬級銆嬶紝涓浗绁炵粡鍏嶇柅瀛﹀拰绁炵粡鐥呭鏉傚織2018骞�11鏈堢25鍗风6鏈� Chin J Neuroimmunol & Neurol 2018锛孷ol.25锛孨o.6锛�387:394
<\/sup>[2] National Multiple Sclerosis Society. Definition of MS. www.nationalmssociety.org\/What-is-MS\/Definition-of-MS<\/a>. Accessed on March 25, 2020<\/span>.
<\/sup>[3] National Multiple Sclerosis Society. What is Myelin? www.nationalmssociety.org\/What-is-MS\/Definition-of-MS\/Myelin<\/a>. Accessed March 25, 2020<\/span>.
<\/sup>[4] Manca R, et al. J Neurol Sci. 2018;388:115-127.
<\/sup>[5] Sumowski JF, et al. Neurology. 2018;90:278-288
<\/sup>[6] Campbell J, et al. Postgrad Med J. 2017;93(1097):143-147.
<\/sup>[7] Deloire, et al. Multiple Sclerosis 2010;16:581鈥�587.   <\/sup>
[8] Comi, G, Kappos, L, Selmaj, KW, et at. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicenter, randomized, minimum 12-month, phase 3 trial. The Lancet: Neurology. DOI: 10.1016\/S1474-4422(19)30239-X.
<\/sup>[9] Cohen, JA, Comi, G, Selmaj, KW, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicenter, randomized, 24-month, phase 3 trial. The Lancet: Neurology. DOI: 10.1016\/S1474-4422(19)30238-8.
<\/sup>[10] National Multiple Sclerosis Society. What Causes MS? www.nationalmssociety.org\/What-is-MS\/What-Causes-MS<\/a>. Accessed March 25, 2020<\/span>.
<\/sup>[11] National Multiple Sclerosis Society. Types of MS. www.nationalmssociety.org\/What-is-MS\/Types-of-MS<\/a>. Accessed March 25, 2020<\/span>.
<\/sup>[12] ZEPOSIA (ozanimod) capsules for oral use. Bristol Myers Squibb Pharmaceutical Corporation. Full prescribing information. 3\/2020.<\/sup><\/p> \n}

 <\/p>"]; $("#dvExtra").html(content_array[0]);})();